BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol. 2005;61:483-490. [PMID: 16021438 DOI: 10.1007/s00228-005-0961-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012;55:566-578. [PMID: 22189484 DOI: 10.1007/s00125-011-2398-8] [Cited by in Crossref: 85] [Cited by in F6Publishing: 73] [Article Influence: 8.5] [Reference Citation Analysis]
2 Robles NR, Fici F, Grassi G. Dihydropyridine calcium channel blockers and renal disease. Hypertens Res 2017;40:21-8. [DOI: 10.1038/hr.2016.85] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
3 Huang R, Feng Y, Wang Y, Qin X, Melgiri ND, Sun Y, Li X. Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis. PLoS One 2017;12:e0168582. [PMID: 28045910 DOI: 10.1371/journal.pone.0168582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Roca-Cusachs A, Triposkiadis F. Antihypertensive effect of manidipine. Drugs 2005;65 Suppl 2:11-9. [PMID: 16398058 DOI: 10.2165/00003495-200565002-00003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
5 Coleman CI, Weeda ER, Kharat A, Bookhart B, Baker WL. Impact of angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria. Diabet Med 2019;37:44-52. [DOI: 10.1111/dme.14107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Verloop WL, Vink EE, Spiering W, Blankestijn PJ, Doevendans PA, Bots ML, Vonken EJ, Voskuil M, Leiner T. Effects of renal denervation on end organ damage in hypertensive patients. Eur J Prev Cardiol 2015;22:558-67. [PMID: 25326543 DOI: 10.1177/2047487314556003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
7 Rashid M, Verhoeven AJM, Mulder MT, Timman R, van Beek-Nieuwland Y, Athumani AA, Zandbergen AAM, van der Wiel HE, Sijbrands EJG, Berk KA. Use of monomeric and oligomeric flavanols in the dietary management of patients with type 2 diabetes mellitus and microalbuminuria (FLAVA trial): study protocol for a randomized controlled trial. Trials 2018;19:379. [PMID: 30012185 DOI: 10.1186/s13063-018-2762-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, Zhao N, Liu L, Lv J, Zhang H, Wang H. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis 2016;67:728-41. [PMID: 26597926 DOI: 10.1053/j.ajkd.2015.10.011] [Cited by in Crossref: 131] [Cited by in F6Publishing: 101] [Article Influence: 21.8] [Reference Citation Analysis]
9 Payeras AC, Sladek K, Lembo G, Alberici M. Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. Clin Drug Investig 2007;27:623-32. [PMID: 17705571 DOI: 10.2165/00044011-200727090-00004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
10 Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S, Chiurchiu C, Barlovic DP, Sghirlanzoni A, Lombardi R, Penza P, Cavaletti G, Piatti ML, Frigeni B, Filipponi M, Rubis N, Noris G, Motterlini N, Ene-iordache B, Gaspari F, Perna A, Zaletel J, Bossi A, Dodesini AR, Trevisan R, Remuzzi G; for the DEMAND Study Investigators. Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus: The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Randomized Clinical Trial. Hypertension 2011;58:776-83. [DOI: 10.1161/hypertensionaha.111.174474] [Cited by in Crossref: 59] [Cited by in F6Publishing: 21] [Article Influence: 5.9] [Reference Citation Analysis]
11 McKeage K, Scott LJ. Manidipine: a review of its use in the management of hypertension. Drugs. 2004;64:1923-1940. [PMID: 15329044 DOI: 10.2165/00003495-200464170-00011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
12 Martinez-Martin FJ, Saiz-Satjes M. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. Expert Rev Cardiovasc Ther. 2008;6:1347-1355. [PMID: 19018688 DOI: 10.1586/14779072.6.10.1347] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
13 Martinez-martin FJ, Macias-batista A, Comi-diaz C, Rodriguez-rosas H, Soriano-perera P, Pedrianes-martin P. Effects of Manidipine and its Combination with an ACE Inhibitor on Insulin Sensitivity and Metabolic, Inflammatory and Prothrombotic Markers in Hypertensive Patients with Metabolic Syndrome: The MARCADOR Study. Clinical Drug Investigation 2011;31:201-12. [DOI: 10.2165/11587590-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
14 Robles NR, Hernandez-gallego R. Blood Pressure in Renal Disease: How to Accomplish the Goal? Cardiovasc Ther 2012;30:193-8. [DOI: 10.1111/j.1755-5922.2010.00260.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
15 Robles NR, Romero B, de Vinuesa EG, Sánchez-Casado E, Cubero JJ. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail 2010;32:192-7. [PMID: 20199181 DOI: 10.3109/08860220903541135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
16 Cavalieri L, Cremonesi G. Metabolic Effects of Manidipine. Am J Cardiovasc Drugs 2009;9:163-76. [DOI: 10.1007/bf03256573] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Coca A. Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. Expert Review of Cardiovascular Therapy 2014;5:147-59. [DOI: 10.1586/14779072.5.2.147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Galceran J, Plana J, Felip A, Pou G, Vila J, Sobrino J. Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers. Expert Rev Cardiovasc Ther 2010;8:751-7. [PMID: 20528630 DOI: 10.1586/erc.10.48] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
19 Fogari R, Mugellini A, Circelli M, Cremonesi G. Combination delapril/manidipine as antihypertensive therapy in high-risk patients. Clin Drug Investig 2011;31:439-53. [PMID: 21627336 DOI: 10.2165/11589000-000000000-00000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Sidorenkov G, Navis G. Safety of ACE inhibitor therapies in patients with chronic kidney disease. Expert Opinion on Drug Safety 2014;13:1383-95. [DOI: 10.1517/14740338.2014.951328] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
21 Rizos CV. Manidipine: A different dihydropyridine. WJH 2011;1:3. [DOI: 10.5494/wjh.v1.i1.3] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
22 Fu C, Wu D, Wang J, Yang W, Tseng C. Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients. Acta Diabetol 2009;46:127-34. [DOI: 10.1007/s00592-008-0069-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
23 Robles NR. Calcium Antagonists and Renal Failure Progression. Renal Failure 2009;30:247-55. [DOI: 10.1080/08860220701856946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]